Yarrow Bioscience, Inc. YARW
Yarrow Bioscience, Inc. (Nasdaq: YARW) is an endocrine/women's health drug developer. Its lead program, YB-101 (GenSci098), is in Phase 1 for Graves' disease; thyroid eye disease planned. Its next catalyst on record is VYN202: Final report of repeat non-clinical toxicology study in male dogs (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VYN202 — Final report of repeat non-clinical toxicology study in male dogs (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| repibresib | Topical pan-BET inhibitor; Phase 2b nonsegmental vitiligo trial terminated July 2025 | small molecule | Phase 2 |
| YB-101 (GenSci098) | Graves' disease and thyroid eye disease (TSHR antibody, clinical-stage) | antibody | Phase 1 |
| VYN202 | Immune-mediated inflammatory disease (oral BD2-selective BET inhibitor; Phase 1b terminated July 2025 after clinical hold; repeat dog tox study) | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.